In the lawsuit filed last week, 44 states attorneys general claim more than a dozen drugmakers conspired to inflate prices for more than 100 generic drugs by as much as 1,000 percent.
Novartis, which owns the Sandoz generic unit, disputed the claims and said it will fight the allegations, which it calls “baseless.”
“We believe that these claims are without merit and will vigorously contest them,” Novartis told Reuters. “Sandoz takes its obligations under the antitrust laws seriously. We will continue to be committed to providing high quality, affordable medicines to U.S. patients, and conducting business with customers and the government with integrity.”
Teva also denied the lawsuit allegations.
“Teva has not engaged in any conduct that would lead to civil or criminal liability,” the company told The New York Times.
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
